These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 596428)
21. Computers, OBRA 90 and the pharmacist's duty to warn. Cacciatore GG Spec Law Dig Health Care Law; 1997 Jul; (221):9-25. PubMed ID: 10168619 [No Abstract] [Full Text] [Related]
22. Package insert and drug liability. Kuzayli M Med Leg Bull; 1972 Feb; 21(2):1-10. PubMed ID: 5061501 [No Abstract] [Full Text] [Related]
23. Labeling regulations: 'prescribe as directed'. Regier H J Leg Med (N Y); 1974; 2(5):48-51. PubMed ID: 4548706 [No Abstract] [Full Text] [Related]
24. Legal implications of preparing and dispensing approved drugs for unlabeled indications. Podell LB Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981 [TBL] [Abstract][Full Text] [Related]
25. The history of patient package inserts in the United States. Moore SR; Morris LA; Groft SC Can Pharm J; 1981 May; 114(5):173-5. PubMed ID: 10251273 [No Abstract] [Full Text] [Related]
26. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121 [TBL] [Abstract][Full Text] [Related]
28. An interview with FDA commissioner Hayes. Small WE Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557 [No Abstract] [Full Text] [Related]
29. The pharmacist's duty under OBRA-90 standards. Brushwood DB J Leg Med; 1997 Dec; 18(4):475-509. PubMed ID: 9433037 [No Abstract] [Full Text] [Related]
30. A means to provide patient education: "Rx package inserts, patient package inserts, device labeling". Sherman M ONA J; 1979 Aug; 6(8):326-9. PubMed ID: 257297 [No Abstract] [Full Text] [Related]
31. ASHP statement on hospital drug control systems. Am J Hosp Pharm; 1974 Dec; 31(12):1198-207. PubMed ID: 4458439 [No Abstract] [Full Text] [Related]
32. The patient medication instruction (PMI) leaflet: regulatory and evidentiary ramifications. Yacura M Spec Law Dig Health Care (Mon); 1986 Mar; 8(1):7-27. PubMed ID: 10276993 [No Abstract] [Full Text] [Related]
33. The legal status of patient package inserts. Whitman JA Hosp Formul; 1978 Oct; 13(10):789-91. PubMed ID: 10238809 [No Abstract] [Full Text] [Related]
34. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues. Thomas JW J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021 [No Abstract] [Full Text] [Related]
35. Some issues related to patient package inserts. Fink JL Hosp Formul; 1979 Feb; 14(2):181-3. PubMed ID: 10240143 [No Abstract] [Full Text] [Related]
36. Patient package inserts--instructions or intrusions? Harvey MW Leg Aspects Med Pract; 1978 Aug; 6(8):47-51. PubMed ID: 703481 [No Abstract] [Full Text] [Related]
37. Expectations of the public regarding pharmaceuticals. Archambault GF Environ Health Ser Radiol Health; 1967 Dec; 30():105-13. PubMed ID: 5600630 [No Abstract] [Full Text] [Related]
38. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm. Furrow BR Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162 [No Abstract] [Full Text] [Related]
39. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule. Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520 [TBL] [Abstract][Full Text] [Related]
40. States boards of pharmacy compounding guidelines. Work DR J Am Vet Med Assoc; 1994 Jul; 205(2):254-5. PubMed ID: 7928592 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]